Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs Year end cash balance of approximately $1.3 billion provides ample liquidity and.
/PRNewswire/ Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced its results for.